Skip to main content
. Author manuscript; available in PMC: 2010 Sep 30.
Published in final edited form as: Am J Geriatr Pharmacother. 2009 Jun;7(3):167–185. doi: 10.1016/j.amjopharm.2009.06.003

Table V.

Agents currently in phase1 trials*

Agent No. of
Patients
(No. of
Trials)		 Mechanism of Action
AFFITOPE AD01
AFFITOPE AD02		 48 (2)
48 (2)		 Active Aβ immunization
GSK933776A 122 (1) Active Aβ immunization
MABT5102A 50 (1) Active Aβ immunization
V950 70 (1) Active Aβ immunization
R1450 60 (1) Passive Aβ immunization
RN1219 NA Passive Aβ immunization
AZD0328 190 (3) α7-Selective NNR agonist
EVP-6124 48 (1) α7-Selective NNR agonist
CTS21166 56 (1) β-Secretase inhibitor
Posiphen NA β-Secretase inhibitor and reduces
APP production
PAZ-417 156 (4) Inhibits plasminogen activator inhibitor-1
(increases clearance of Aβ)
GSI-953 153 (3) γ-Secretase inhibitor
GSK239512 41 (2) H3 receptor antagonist
CERE-110 10 (1) Gene therapy
EVT101 NA NR2B subunit containing NMDA
antagonist
Nicotinamide
(vitamin B3)		 50 (1) Inhibits tau hyperphosphorylation
*

Data source for this table is www.clinicaltrials.gov. Accessed Jan 13, 2009